Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

Journal of Clinical Investigation

Volumn 107, Issue 10, 2001, Pages 1235-1244

  Zhang, Jian ^a   Dai, Jinlu ^a   Qi, Yinghua ^b   Lin, Din Lii ^a   Smith, Peter ^a   Strayhorn, Chris ^a   Mizokami, Atsushi ^c   Fu, Zheng ^a   Westman, John ^a   Keller, Evan T ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b The Municipal 3rd Hospital of Tianjin   (China)

^c KANAZAWA UNIVERSITY   (Japan)

^d CCGCB Box 0940 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; METASTASIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; TIBIA; TUMOR GROWTH;

EID: 0035021176     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11685     Document Type: Article

References (45)

1. Metastases in carcinoma
2. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia
3. Generalised increase in bone resorption in carcinoma of the prostate
4. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer
5. The effects of pamidronate disodium treatment in metastatic prostate cancer
6. Bone resorption by osteoclasts
7. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cotd
8. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines
9. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
10. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice
11. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance
12. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice
13. Cytokines, growth factors and osteoclasts
14. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
15. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
16. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines
17. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
18. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines
19. Calcium studies in ten cases of osteoblastic prostatic metastasis
20. Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension
21. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment
22. Establishment of a model to evaluate inhibition of bone resorption induced by human prostate cancer cells in nude mice
23. Heterogenous bone histomorphometric patterns in metastatic prostate cancer
24. Molecular mechanisms of osteolytic bone metastases
25. Markers of bone turnover for the management of patients with bone metastases from prostate cancer
26. Markers of bone turnover in bone metastases
27. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
28. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer
29. Optimising treatment of bone metastases by arediatm and zometatm
30. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
31. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis
32. Differences in static cortical bone remodeling parameters in human mandible and iliac crest
33. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: Study in eumenorrheic patients with Cushing's syndrome
34. Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: Relevance to the pathogenesis of bone loss
35. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
36. Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue
37. Expression of membrane-type 1 matrix metalloproteinase (MTI-MMP) on prostate cancer cell lines
38. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: Differentiation is associated with repression of metalloproteinase biosynthesis
39. Breast cancer cells interact with osteoblasts to support osteoclast formation
40. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
41. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
42. The bone metastatic LNCaP-derivative C4-2B prostate cancer cell line induces mineralization in vitro
43. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
44. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse
45. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease